{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":16,"youtube":12,"x_thread":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03888105\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ELM-2","nct_id":"NCT03888105","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=elm-2-nct03888105. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ELM-2","arms":[{"description":"Follicular lymphoma grade 1-3a cohort","label":"FL","type":"EXPERIMENTAL"},{"description":"Diffuse large B-cell lymphoma cohort","label":"DLBCL","type":"EXPERIMENTAL"},{"description":"Mantle Cell Lymphoma cohort","label":"MCL","type":"EXPERIMENTAL"},{"description":"Marginal Zone Lymphoma cohort","label":"MZL","type":"EXPERIMENTAL"},{"description":"Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia \\[WM\\]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed","label":"Other B-NHL","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-15","type":"ESTIMATED"},"conditions":["B-cell Non-Hodgkin Lymphoma (B-NHL)"],"enrollment":{"count":515,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Odronextamab","type":"DRUG"}],"last_update":"2026-07-31","lead_sponsor":"Regeneron Pharmaceuticals","official_title":"An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR), as assessed by independent central review","timeFrame":"Up to 52 weeks of study treatment"},{"measure":"ORR, as assessed by independent central review","timeFrame":"Up to 36 weeks of study treatment"}],"references":[{"citation":"Villasboas JC, Poon M, Tani M, Jimenez-Ubieto A, Tessoulin B, Warwick L, Brown D, Namuduri M, Lin C, Delwart V, Jagadeesh D. Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study. Future Oncol. 2026 Mar;22(6):643-658. doi: 10.1080/14796694.2026.2628111. Epub 2026 Mar 1.","pmid":"41766170","type":"DERIVED"},{"citation":"Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J. Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Adv. 2025 Dec 9;9(23):6130-6140. doi: 10.1182/bloodadvances.2025016332.","pmid":"40902079","type":"DERIVED"},{"citation":"Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.","pmid":"40472301","type":"DERIVED"},{"citation":"Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17.","pmid":"40097657","type":"DERIVED"}],"start_date":{"date":"2019-11-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies","url":"https://clinicaltrials.gov/study/NCT03888105"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/elm-2-nct03888105"}